Penggunaan Antibiotik Pada Pasien Pneumonia Covid-19: Studi Kuantitatif Pada Rumah Sakit Dr. R. Goeteng Taroenadibrata Purbalingga

Akhmad Haris Suseno; Anjar Mahardian Kusuma; Githa Fungie Galistiani; Gangga Harima

doi:10.54350/jkr.v14i2.443

Akhmad Haris Suseno Program Studi Farmasi, Fakultas Kesehatan, Universitas Muhammadiyah Purwokerto
Anjar Mahardian Kusuma Program Studi Farmasi, Fakultas Kesehatan, Universitas Muhammadiyah Purwokerto
Githa Fungie Galistiani Program Studi Farmasi, Fakultas Kesehatan, Universitas Muhammadiyah Purwokerto
Gangga Harima Instalasi Farmasi RSUD Dr. R. Goeteng Taroenadibrata Purbalingga

DOI: https://doi.org/10.54350/jkr.v14i2.443

Abstract

Covid-19 is a problem for the world and Indonesia. Pneumonia is one of the most common comorbid diseases of Covid-19. The management of Covid-19 pneumonia is using empirical antibiotics. Inappropriate use of antibiotics can lead to antibiotic resistance so it is very necessary to evaluate the use of antibiotics. The purpose of this study was to determine the quantity of antibiotic use in patients with Covid-19 pneumonia at Dr. R. Goeteng Taroenadibrata Purbalingga Hospital. This study used a cross sectional research design using retrospective data with observational research. The method of evaluating antibiotic use uses the ATC/DDD methods. Based on the evaluation using the ATC/DDD method, The DDD/100 patient-days value of antibiotic use was intravenous Azithromicin (52,860 DDD/100 patient-days), Ceftriaxone (42,412 DDD/100 patient-days), peroral Azithromicin (8,582 DDD/100 patient-days), Levofloxacin (6,529 DDD/100 patient-days), Cefixime (2,985 DDD/100 patient-days), Ciprofloxacin (1,243 DDD/100 patient-days), Cefotaxime (2,798 DDD/100 patient-days) and Metronidazole (1,119 DDD/100 patient-days). There are 2 types of antibiotics that meet WHO standards and 6 types of antibiotics that do not meet WHO standards.

References

Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54.

WHO. WHO. 2023. Dasbor Virus Corona WHO (COVID-19).

Kemenkes. Kemkes.go.id. 2023. PEMANTAUAN KASUS COVID-19 PROVINSI JAWA TENGAH UPDATE TERAKHIR 21 Juni 2023 16:00.

AndraFarm. AndraFarm.com. 2023. Berita kasus perkembangan virus Corona di Provinsi Jawa Tengah per hari hingga tanggal 3 Oktober 2023.

Ng TM, Ong SWX, Loo AYX, Tan SH, Tay HL, Yap MY, et al. Antibiotic Therapy in the Treatment of COVID-19 Pneumonia: Who and When? Antibiotics. 2022;11(2):1–9.

Rozaliyani A, Savitri AI, Setianingrum F, Shelly TN, Ratnasari V, Kuswindarti R, et al. Factors Associated with Death in COVID-19 Patients in Jakarta, Indonesia: An Epidemiological Study. Acta Med Indones. 2020;52(3):246–54.

Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.

Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622–9.

Kemenkes RI. Peraturan Menteri Kesehatan Nomor 8 Tahun 2015 tentang Program Pengendalian Resistensi Antimikroba Di Rumah Sakit. Proceedings of the National Academy of Sciences. Jakarta; 2015.

WHO. GLASS methodology for surveillance of national antimicrobial consumption. WHO, editor. WHO; 2020. 1–68 p.

Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J. 2020;318(6).

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061–9.

Fahmia R, Helda H, Nursari AY. Lama Rawat Inap Pasien Terkonfirmasi COVID-19 di Rumah Sakit Universitas Indonesia dan Faktor yang Mempengaruhinya. J Epidemiol Kesehat Indones. 2022;6(1):1–12.

WHO. Guidelines for ATC classification and DDD assignment 2023. 26th ed. Oslo: Norwegian Institute of Public Health; 2023. 252 p.

Nugraha Putra O, Studi Farmasi P, Kedokteran F, Purwaningtyas M, Ratna Oktaviani C. Evaluasi Penggunaan Antibiotik Pada Pasien COVID-19 Pneumonia di Ruangan ICU Dengan Metode ATC/DDD. Pharm J Indones. 2023;2023(2):135–42.

Dewi AK, Sitorus MF. EVALUASI PENGGUNAAN ANTIBIOTIK PASIEN COVID-19 MENGGUNAKAN METODA GYSSENS DAN ATC/DDD DI RSAU Dr. M. SALAMUN KOTA BANDUNG. Med Sains J Ilm Kefarmasian. 2023;8(2):713–22.

Aseng CR, Wiyono WI, Jayanti M, Program ), Farmasi S, Matematika F, et al. Evaluasi Penggunaan Antibiotik pada Pasien Covid-19 di RSUP Prof. Dr.R. D. Kandou Manado Periode Januari-Maret 2021. Pharmacon– Progr Stud Farm Fmipa, Univ Sam Ratulangi. 2023;12(1):77–82.

Schwartz RA, Suskind RM. Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration. Dermatol Ther. 2020;33(4):2–4.

Thapa B, Pathak SB, Jha N, Sijapati MJ, Shankar PR. Antibiotics Use in Hospitalised COVID-19 Patients in a Tertiary Care Centre: A Descriptive Cross-sectional Study. J Nepal Med Assoc. 2022;60(251):625–30.

Burhan E, Susanto AD, Nasution SA, Eka G, Pitoyo ceva W, Susilo A, et al. Pedoman tatalaksana COVID-19 edisi 4. Pedoman tatalaksana COVID-19 edisi 4. 2022. 79–85 p.